OncoMatch/Clinical Trials/NCT06859775

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Is NCT06859775 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for recurrent or metastatic cervical cancer.

Phase 1/2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775Data as of May 2026

Treatment: SHR-A1811 · Adebelimab · Bevacizumab · SHR-8068 · Cisplatin · Carboplatin — This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Metastatic disease required

Lab requirements

Blood counts

Normal function of vital organs

Kidney function

Normal function of vital organs

Liver function

Normal function of vital organs

Cardiac function

Normal function of vital organs

Normal function of vital organs

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify